Clinical Trial News

SeaStar Medical activates 14th site for NEUTRALIZE-AKI trial, evaluating SCD device for AKI patients on CRRT. 70 of 200 planned subjects enrolled, with interim analysis expected mid-2025. SCD targets hyperinflammation, with potential U.S. market of $4.7B-$6.3B for AKI treatment.

Protalix BioTherapeutics, Inc. shares accomplishments in 2024, including EMA validation for pegunigalsidase alfa dosing, phase I trial results for PRX-115, and repayment of convertible notes. The company looks forward to advancing PRX-115 and pipeline developments in 2025.

UiB researchers discovered NAD's role in cellular energy metabolism and vital functions, with mitochondria acting as NAD reservoirs. Dysregulated NAD levels link to aging and diseases like cancer, diabetes, and neurodegenerative disorders. NAD supplementation shows promise in clinical trials.

Protalix BioTherapeutics announces significant milestones in 2024, including EMA validation for a less frequent dosing regimen for Fabry disease, progress in PRX-115 clinical trials, and repayment of all outstanding convertible notes, positioning the company for long-term growth.

NanoViricides, Inc. claims NV-387, a broad-spectrum antiviral, is effective against H5N1 bird flu, as it mimics host-side features the virus relies on. NV-387 outperformed existing influenza drugs in animal studies and has completed Phase I human trials with no adverse events. The company is preparing Phase II trials for MPox and respiratory virus infections.

Zura Bio launches TibuSURE, a Phase 2 study evaluating tibulizumab for systemic sclerosis, targeting anti-BAFF and IL-17 pathways.

Protalix BioTherapeutics shares 2024 milestones, including EMA validation for less frequent dosing of pegunigalsidase alfa for Fabry disease, phase I trial results for PRX-115, and repayment of convertible notes. The company looks forward to advancing PRX-115 into phase II in 2025 and continuing growth in sales.

Zura Bio launches TibuSURE, a global Phase 2 study evaluating tibulizumab for systemic sclerosis in adults, targeting both anti-BAFF and IL-17 pathways for deeper efficacy.

Pfizer gains FDA accelerated approval for BRAFTOVI (encorafenib) with cetuximab and mFOLFOX6 to treat metastatic colorectal cancer with BRAF V600E mutation, based on Phase III BREAKWATER trial results showing 61% response rate. Approval contingent on further clinical benefits verification.